VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates to a virus-like particle vaccine comprising flavivirus structural proteins to prevent or treat flavivirus infection. Flavivirus includes dengue virus, West Nile virus, Japanese encephalitis, hepatitis C virus, and Zika virus.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN) today announced it has entered into definitive agreements with institutional investors to purchase approximately 5.77 million shares of its common stock and warrants exercisable for up to approximately 5.77 million shares of its common stock for gross proceeds of approximately $7.5 million. The shares and warrants are being sold in units, each consisting of one share of common stock and a warrant to purchase one share of common stock, at an offering price of $1.30 per unit. The warrants will be exercisable six months following the date of issuance, will expire on the fifth anniversary of the initial exercise date and will have an exercise price of $1.67 per share. The closing of the offering is expected to take place on or about October 19, 2018, subject to the satisfaction of customary closing conditions.

Top 3 by 2023

State of the BioHealth Capital Region’s EcoSystem

Rich Bendis

President & CEO, BioHealth Innovation Inc.

Pharma hasn’t traditionally been known as a sector that welcomed innovation from the outside. But now companies are putting “not invented here” bias aside as they seek to widen their aperture for innovation.

Based in Rockville, MD

Management Recruiters – Mid Hudson Valley is an executive search firm focused solely in serving the nonprofit sector.  We have a national practice and the large majority of our placements are executive leadership and senior fundraising professionals.

Our client is Montgomery College, a community college of more than 60,000 students in Montgomery County, MD. The College is seeking a Vice President for Development and Alumni Relations who also serves as the Executive Director of the Montgomery College Foundation. The position is a College employee.

The Cybersecurity Association of Maryland, Inc. (CAMI) and Universities at Shady Grove invite you to attend their November 9 & 10 Maryland Cybersecurity Career & Education Fair.

Maryland is at the forefront of our nation’s rapidly growing cyber market and opportunities abound for professionals in our region—both those who are new to the field, and long-time members of the industry. Join us at the Universities at Shady Grove for two dynamic days that put on display why Maryland is where cyber works. Friday will feature a career and education fair, connecting cybersecurity job seekers with opportunities across the state of Maryland. Those looking to expand their cybersecurity competency can also connect on-site with Maryland education and training resource. On Saturday, cyber warriors of high school through undergraduate skill levels are invited to compete in our "Catch the Phish: An AI Capture the Flag Event" cyber challenge.

MaxCyte, the global cell-based medicines and life sciences company, announced today that the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the Company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

More than 300 representatives of companies from throughout the BioHealth Capital Region took over BowlMore Gaithersburg last Thursday for a fun evening of networking. The 5th annual BioBowl cohosted by MedImmune and BioHealth Innovation included teams from Baltimore and DC to Montgomery and Frederick counties. Qiagen took home the First Place prize and the Women in Bio event were recognized for their efforts with a Rubber Chicken Award.

Have you register for this year’s Women Building Bio event? The third Annual Women Building Bio Conference is taking place October 17 at the Inova Center for Personalized Health. This is a one-day regional conference converging extraordinary men and women, industry and academia, researchers and innovators, professionals and decision-makers gathering together to cultivate relationships and making an impact. Click here for the agenda and more information. (For a discount code, email This email address is being protected from spambots. You need JavaScript enabled to view it. and register by 3 p.m., Tuesday, October 16th.)

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious diseases. With the closing of this transaction, Emergent acquires two marketed vaccines – Vivotif® (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the U.S. Food and Drug Administration (FDA) for the prevention of typhoid fever, and Vaxchora® (Cholera Vaccine, Live, Oral), the only FDA-licensed vaccine for the prevention of cholera, a potentially serious intestinal disease, caused by Vibrio cholerae serogroup O1. The acquisition broadens the company’s development pipeline with vaccines that address adenovirus types 4 and 7, which are common causes of acute respiratory disease, and chikungunya, a viral disease spread to humans by infected mosquitoes that can cause severely debilitating joint pain. The acquisition also expands the company’s sales capabilities with a global specialty salesforce and marketing and distribution partners focused on the travelers’ market and establishes an international manufacturing footprint with European-based cGMP biologics facilities.

Pharma major Lupin announced that it has received tentative approval for its Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg from the United States Food and Drug Administration (FDA) to market a generic version of Sunovion Pharmaceuticals Inc.’s (Sunovion) Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.

Lupin’s Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg is the generic version of Sunovion’s Latuda Tablets, 20 mg, 40 mg, 60 mg, 80 mg and 120 mg.

The Food and Drug Administration approved or tentatively approved a record-setting 971 generic drugs in fiscal year 2018 that ended last month, the agency announced on Thursday.

The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) has been renewed for funding under a cooperative agreement grant from the U.S. Food and Drug Administration (FDA). A collaborative partnership led by James Polli, PhD, the Shangraw/Noxell Endowed Chair in Industrial Pharmacy and Pharmaceutics at the University of Maryland School of Pharmacy, and William E. Bentley, PhD, the Robert E. Fischell Distinguished Chair of Engineering at the University of Maryland, College Park (UMCP), M-CERSI is one of only four FDA-funded CERSIs in the U.S., and the only CERSI to receive continuous funding from the FDA since it first launched in 2011. This latest renewal, which allows for up to $5 million per year over five years, will allow M-CERSI to continue its mission to contribute to modernizing and improving the ways in which drugs and medical devices are reviewed and evaluated.

Montgomery County is proving to be a premium address for the growing biotechnology sector. 

The BioHealth Capital Region, which includes Maryland, Virginia and Washington D.C., is ranked No. 4 on the 2018 list of top biopharma centers by Genetic Engineering & Biotechnology News (GEN). The cluster moves up from a No. 5 ranking in 2017.

GEN ranks regions nationally based on several factors, including National Institutes of Health (NIH) funding, venture capital investment, patents, lab space and jobs in biotech. 

Five consecutive quarters—and counting—of declining deal counts in pre-seed and seed-level investments for health technology startups in the U.S.

We're thrilled to announce Molly McCartin, Partner, Drive Capital, will be a featured speaker at the Fall 2018 Inova Discovery Series!

Molly McCartin is an investing partner with a focus on healthcare at Drive Capital, a venture capital firm based in Columbus, OH founded by two former Sequoia partners. Molly started her career at JP Morgan Chase in Equity Research. She then moved to 7Wire Ventures investing in healthcare companies that empower the health consumer. Molly spent the last four years at Livongo Health, helping the company grow from 6 employees to over 150 and over 200 customers. Molly graduated from MIT with a degree in Applied Math and Economics.

It’s cybersecurity month at Technical.ly and this new accelerator program is here to heat up the discussion.

There are lessons for other industries in the way pharma companies use mergers to innovate, work more efficiently, and bolster product portfolios.

Baltimore-based AgeneBio announced a pair of grants from the National Institutes of Health that will assist with clinical trials of a treatment to combat the progression of Alzheimer’s disease.

MaxCyte announced the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the company's lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.

However long a business has operated, investors will look for three big things if they are going to invest.

U.S. healthcare companies have collected $23.4 billion in venture capital funding this year — already surpassing the amount the sector obtained in all of 2017, according to a recent report from Pitchbook, which tracks VC investments.

The number of open innovation challenges in pharma grows by the day. But what’s driving them? That’s what Luminary Labs wanted to know. So the consultancy, which works with pharma and other industries to design and execute those kind of challenges, surveyed the executives at companies that run the contests and asked why and how they do it.

The first Biohealth Capital Region Investment Conference kicks off this week in Montgomery County. The conference marks an important inflection point for a region whose entrepreneurs have been calling for more active investment resources for years.  The event also fulfills a promise made by organizers at past BioHealth Capital Region Forums to bring more investment activity to the region.

Europe’s biotech industry recently celebrated its growth and progress with more than 120 events taking place across 18 European countries September 24 –30, in what organizers call “European Biotech Week.”

Biopharma venture capital activity maintained its red-hot pace during the third quarter of 2018, driven by a handful of deals exceeding $200 million, according to a report released this week.

This has been a year marked by many notable biotech deals, especially in the immunotherapy market.  One deal, in particular, has generated more local excitement in the BioHealth Capital Region than any other; that is the BeneVir acquisition by Janssen, a JNJ company.  Likewise, of the many startup stories and local entrepreneurs we’ve highlighted this past year, none is as unique and interesting as that of BeneVir Co-Founder and COO, Katherine (Katie) Sacksteder, PhD.

Johns Hopkins Center for Health Security authors recommend dedicated attention to and investment in 'potentially transformative' technologies to complement traditional approaches to prevention, preparedness, and response

The Center for Innovative Technology (CIT) announced today the Commonwealth Research Commercialization Fund (CRCF) Request for Proposals (RFP) for FY2019.

Some big cities could see shortages of cancer specialists in the coming decade, according to a new analysis by Doximity, a social network for more than a million physicians. Researchers at the company delved into the data on oncologists and found there’s an imminent wave of retiring physicians. The areas most likely to see shortages: Miami, Virginia Beach, and Tampa. But other cities could also see large portions of the cancer physician workforce retire relatively soon. In half of the 50 metropolitan areas surveyed, more than 20 percent of practicing oncologists are over age 65.

The local funding environment is mirroring the gangbusters national funding situation.

Valneva USA, the U.S. subsidiary of global vaccine biotech company Valneva SE, today announced U.S. Food and Drug Administration (FDA) approval of an accelerated dosing regimen for IXIARO® (Japanese Encephalitis Vaccine, Inactivated, Adsorbed), the only vaccine approved in the United States indicated for protection against disease caused by Japanese encephalitis (JE) virus.

BioHealth Innovation sponsors quarterly office hours in Montgomery County and at Johns Hopkins Fast Forward (Fast Forward hours are for JHU innovators only).

BioHealth Capital Region innovators not located at Fast Forward can register for SBIR office hours on the following dates.

• Tuesday - Nov 6, 8:00 a.m. – 12:00 p.m. – Germantown Innovation Center
• Wednesday - Nov 7, 1:00 – 5:00 p.m. – Rockville Innovation Center
• Tuesday – Feb 12, 8:00 a.m. – 12:00 p.m. - Germantown Innovation Center
• Wednesday --Feb 13, 1:00 – 5:00 p.m. - Rockville Innovation Cente
• Wednesday – May 8, 8:00 a.m. – 12:00 p.m.- Germantown Innovation Center
• Thursday -- May 9, 1:00 – 5:00 p.m. - Rockville Innovation Center

To register for the open sessions, click here.  (BHI also will be hosting a more general SBIR overview with office hours on January 29, 2019.  Mark your calendar; more details to follow.)

If you and your team are located in the BioHealth Capital Region, BHI may prepay for experts to help you improve your SBIR and other non-dilutive funding applications for biohealth related projects. Your only obligation is that if you win the award, you reimburse BHI for the consulting fees (typically $1500 or $3000) and a minimal program management fee (ten % of the prepaid consulting fee i.e. $150 or $300).

For more information contact This email address is being protected from spambots. You need JavaScript enabled to view it..